GlaxoSmithKline Pharmaceuticals Limited — PPTs, 13-05-2026: Investor Presentation

**Business Performance:** GSK India delivered strong FY26 financials with standalone revenue at ₹3,790 Cr (+2% YoY) and record Profit After Tax (PAT) of ₹1,010 Cr (+10% YoY). Q4 revenue was ₹989 Cr (+2% YoY) with PAT at ₹275 Cr (+6% YoY), despite some supply/vaccine challenges. GSK's represented market grew 7.3%, while the acute market saw 8.9% growth. Its General Medicines market share is improving.

**Growth Drivers or Strategy:** The company is focusing on growth for both established and innovative portfolios, accelerating R&D, and simplifying operations with AI/tech. A clear shift to specialty and innovative products contributed 6% of Q4 sales. Key initiatives include boosting adult immunization via Shingrix (56% YoY Rx growth) and strengthening the respiratory segment.

**Recent Developments:** Highlights include RUBY-1 approval (Oncology) expanding patient eligibility, and Blenrep's marketing authorization with an India launch expected in Q4 2026. Also, 26 clinical trials are ongoing. A final dividend of ₹57 per share was declared.

**Key Financial Metrics:** EBITDA margin expanded to 34.3% for FY26 (+290 bps YoY) and 35.1% for Q4 (+90 bps YoY), driven by better gross margins and cost efficiencies. FY26 EPS was ₹59.6 (+10%), Q4 EPS ₹16.23 (+6%), with year-end cash at ₹2,746 Cr.

**Management Commentary / Outlook:** Management foresees continued profitable growth and margin expansion, supported by portfolio transformation and disciplined cost management through improved field force and AI optimization. Focus for 2026 includes unlocking growth via CVMD opportunities and broader market access.